WASHINGTON, DC and DENVER, JANUARY 6, 2021 – The Global Liver Institute (GLI), the only patient-led liver health nonprofit operating internationally, in partnership with TriSalus Life...
Fatty liver disease (FLD) and nonalcoholic steatohepatitis (NASH) are increasing in prevalence worldwide, creating a major global public health crisis. To adequately educate patients, practitioners,...
POLICY PERSPECTIVE In the past, efforts in liver advocacy were siloed by individual liver disease lessening their impact and limiting their effectiveness at shaping national health policy. In 2021...
On February 4, 2022 10 AM ET, Global Liver Institute led an Externally-Led Patient-Focused Drug Development Meeting (EL-PFDD) on Primary Biliary Cholangitis (PBC). This online event is open to the...
Donna R. Cryer, JD, President and CEO, Honored with Awards from the American Association for the Study of Liver Diseases (AASLD) and Global Genes for leadership in connecting, empowering, inspiring...
POLICY PERSPECTIVE The liver advocacy community — with the GLI Liver Action Network leading the way — has elevated patient voices through a variety of initiatives throughout September and October....
Fatty liver disease (FLD) and nonalcoholic steatohepatitis (NASH) are increasing in prevalence worldwide, creating a major global public health crisis. To adequately educate patients, practitioners,...
Dear Colleague: October is Liver Cancer Awareness Month. This represents an opportunity to draw attention to the global burden of liver cancer and to highlight the various public health...
On November 4th at 10 AM ET, Global Liver Institute led an Externally Led Patient-Focused Drug Development Meeting on NASH for the FDA. This online event is open to the public with registration...
(Washington, DC, Friday, October 22, 2021)—Global Liver Institute (GLI) CEO and President, Donna R. Cryer, JD, yesterday applauded the actions of U.S. Representative Nydia Velázquez...
Recent News
Together for Better Liver Health: WHA78 Side Event Unites Global Stakeholders to Strengthen Public Health Responses to Metabolic DiseaseGeneva, Switzerland - 23 May 2025 - Global health leaders call for urgent, integrated action on the rising rates of metabolic liver...
Global Health Leaders Convene at WHA78 Side Event to Advocate for Steatotic Liver Disease as a Core Non-Communicable DiseaseGeneva, Switzerland – 22 May 2025 – Leading health organizations, policymakers, and public health advocates will come together during the 78th...
The Frontline Role of Primary Care in Hepatitis B CareChronic infection of the liver by hepatitis B virus (HBV) remains a significant public health concern in the U.S. and around the world, particularly among at-risk populations. Although many people who are infected...
Congress returns with budget reconciliation at the top of the to-do list. Key House authorizing committees are slated to kick off markups on their respective budget reconciliation instructions that will be combined into a single reconciliation bill. Join Global Liver...
Big Wins for Rare Liver Disease: New Codes, Drug Approvals, and Global Advocacy – Pediatric and Rare Liver Diseases News New ICD-10 Codes for Fontan-Associated Conditions The introduction of new, dedicated ICD-10 diagnosis codes for Fontan-associated...
